Vesalius Biocapital III Announces Significant Investment from the European Investment Fund

Luxembourg-Bertrange, January 17th, 2019Vesalius Biocapital III, the specialist life sciences venture capital investor, announces an investment of €30 million by the European Investment Fund (EIF). This secures commitments of €110 million to date. Until the final closing, scheduled for end April 2019, Vesalius Biocapital III will accept new investors on a “rolling closing” basis. The fund will invest in later-stage European life sciences companies, providing capital to support their development. Vesalius Biocapital III has executed three investments to date.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...